Sep 15, 2026
Enhertu demonstrated a median progression-free survival of 14.3 months as 1st-line therapy in patients with HER2-mutant advanced non-small cell lung cancer in DESTINY-Lung04 Phase III trial“In the primary endpoint of PFS, Enhertu monotherapy significantly reduced the...
Sep 8, 2026
Inhaled Microplastics Linked To Lung Cancer, Study Finds“About 66% of lung cancer patients had detectable microplastics found in fluid samples taken from their lungs, compared to 46% of people without lung cancer, researchers reported Sunday at a meeting of the...
Aug 5, 2026
FDA Approves Zidesamtinib for ROS1-Positive Non-Small Cell Lung Cancer “On July 22, the U.S. Food and Drug Administration (FDA) approved zidesamtinib (Jideytro) for adults with locally advanced or metastatic ROS1-positive non-small cell lung cancer (NSCLC) who were...
Jul 21, 2026
Specialist Microscopy and AI Analysis Can Improve Lung Cancer Testing“Research shows fluorescence lifetime imaging microscopy (FLIM) combined with a form of artificial intelligence (AI) known as deep learning can predict if a person has lung cancer-related EGFR...
Jul 14, 2026
Improving neoadjuvant and perioperative therapy in non-small-cell lung cancer“Neoadjuvant chemoimmunotherapy, comprising an anti-PD-(L)1 antibody and platinum-doublet chemotherapy, given alone or as part of a perioperative regimen with the addition of adjuvant...
More News and Updates